|Idenix Pharmaceuticals Inc.|
60 Hampshire Street
United States - Map
Idenix Pharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, engages in the discovery and development of drugs for the treatment of human viral diseases in the United States and France. Its primary research and development focus is on the treatment of patients with hepatitis C virus (HCV). The companys HCV discovery program focuses on various classes of drugs, including nucleoside/nucleotide polymerase inhibitors, NS5A inhibitors, protease inhibitors, and non-nucleoside polymerase inhibitors. It also develops non-nucleoside reverse transcriptase inhibitors for the treatment of human immunodeficiency (HIV) virus type-1 and acquired immune deficiency syndrome (AIDS); and products and drug candidates for the treatment of patients with hepatitis B virus (HBV). The company has a collaboration agreement with Janssen Pharmaceuticals, Inc.; ViiV Healthcare Company; Novartis; and GlaxoSmithKline. Idenix Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
|Idenix Pharmaceuticals Inc.’s ISS Governance QuickScore as of Mar 1, 2014 is 4. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 1; Compensation: 6.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Ronald C. Renaud Jr.,
Chief Exec. Officer, Pres and Director
|Ms. Daniella Beckman ,
Chief Financial Officer, Principal Accounting Officer, Sr. VP and Treasurer
|Ms. Maria D. Stahl ,
Sr. VP, Gen. Counsel and Sec.
|Dr. Douglas L. Mayers M.D.,
Chief Medical Officer and Exec. VP of Clinical Devel.
|Dr. Jacques Dumas Ph.D.,
Chief Scientific Officer and Exec. VP
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|